Dovramilast

Research use only, not for human use.

Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor that reduces the production of pro-inflammatory mediators and cytokines.

Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).

——

Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology. Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice.Animal Model:B6D2F1 mice Dosage:5, 25, or 50 mg/kg Administration:oral, 5, 25, or 50 mg/kg, single Result:Reduced PDE4 expression in mtb-infected mouse lungs.Animal Model:B6D2F1 mice Dosage:5, 25, or 50 mg/kg Administration:oral gavage, 5, 25, or 50 mg/kg, single Result:Improved antibiotic-mediated bacterial killing and reduced lung pathology.

——

Angiogenesis

PDE

PDE

——

——

340019-69-4

472.55

C24H28N2O6S

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (52.90 mM; Ultrasonic (<60°C)

CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1Cc2cccc(NC(=O)C3CC3)c2C1=O

——

(-20℃)

With Ice Pack

≥ 2 years